Univercells R&D / Quantoom Biosciences

Qui sommes-nous ?

At Univercells, we are on a mission to make health equally accessible to all. Through the combination of process development and engineering expertise, we create synergies to deliver game-changing production capacities to achieve our mission: biologics for all. 

At Quantoom Biosciences/Univercells R&D, a Univercells company, we are on a mission to remove the barriers to making mRNA-based vaccines and therapeutics, at every stage from sequence up to mass production. We give our partners greater access to drug development and production autonomy through technical and business model innovation. Quantoom Biosciences/Univercells R&D is proud to host an interdisciplinary team of passionate scientists, engineers, technicians, and corporate profiles committed to solving some of the biggest challenges in DNA- and RNA manufacturing for vaccines and therapeutics. Quantoom Biosciences/Univercells R&D has two facilities; the headquarters are based in Nivelles (Belgium), and the France Research Center focusing on offering an end-to-end DNA production platform based in Evry (France).

In addition to its current focus area of mRNA-based vaccination, Quantoom/Univercells R&D is continuously exploring new applications for its current and future development projects, including cell-free protein synthesis, DNA vaccines, RNA-based therapeutics, gene delivery technologies, and many more.

Pourquoi nous rejoindre ?

At Univercells, we are on a mission to make health equally accessible to all. We work every day to reinvent biomanufacturing processes and develop or integrate the next innovative technologies. Through the combination of process development and engineering expertise, we create synergies to deliver game-changing production capacities to achieve our mission: “Biologics available and affordable to all!”

• Univercells SA brings together a group of Belgian and global biotech affiliates working together under a common mission (the “Group”). Each division of affiliates operates a different part of the healthcare value chain, through a distinct business model:
• Exothera is a contract research, development, and manufacturing organization (CRDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services and process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. 
• Unizima delivers international project management of technology transfer, alongside operational support services (quality, supply chain, digital) and bioproduction training programs, as well as care centers and diagnostics surveillance centers.
• Quantoom Biosciences is reinventing mRNA production by developing an mRNA production platform (NfinityTM) from sequence up to mass production.
• RLM Consulting thanks to a substantial knowledge of the pharmaceutical industry and a strong scientific background, RLM Consulting provides international regulatory affairs support at all stages of product development, from discovery research through preclinical and clinical testing, up to and beyond submission of the dossier for marketing authorization.

We deliver excellence and strive for innovation thanks to collaborative teams of passionate change-makers. We are driven by 5 core values in everything we do: Accountability, Continuous Improvement, Teach & Lead, Integrity, and Team spirit.